{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:58:50Z","timestamp":1791215930408,"version":"4.1.0"},"reference-count":88,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"DOI":"10.1093\/eurheartj\/ehv755","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T10:55:38Z","timestamp":1487156138000},"page":"317-325","source":"Crossref","is-referenced-by-count":58,"title":["Agents with vasodilator properties in acute heart failure"],"prefix":"10.1093","volume":"38","author":[{"given":"Abhishek","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efd","family":"Laribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,2,4]]},"reference":[{"key":"key\n\t\t\t\t20170215191336_EHV755C1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11897-014-0221-9","article-title":"Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes","volume":"11","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"key\n\t\t\t\t20170215191336_EHV755C2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST)","volume":"134","year":"1997","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","article-title":"Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"149","year":"2005","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00134-010-2113-0","article-title":"Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF)","volume":"37","year":"2011","journal-title":"Intensive Care Med"},{"key":"key\n\t\t\t\t20170215191336_EHV755C5","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/eurheartj\/ehl193","article-title":"EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population","volume":"27","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C6","doi-asserted-by":"crossref","first-page":"R291","DOI":"10.1186\/cc10584","article-title":"Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry","volume":"15","year":"2011","journal-title":"Crit Care"},{"key":"key\n\t\t\t\t20170215191336_EHV755C7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2011.09.020","article-title":"Admission time, variability in clinical characteristics, and in-hospital outcomes in acute heart failure syndromes: findings from the ATTEND registry","volume":"153","year":"2011","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/eurjhf\/hfs117","article-title":"Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome","volume":"14","author":"IN-HF Outcome Investigators","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ejheart.2006.01.001","article-title":"Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study","volume":"8","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ahj.2011.03.033","article-title":"The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry","volume":"162","year":"2011","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C11","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archinternmed.2012.3310","article-title":"The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries","volume":"172","year":"2012","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170215191336_EHV755C12","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/eurheartj\/eht393","article-title":"Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)08417-1","article-title":"Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170215191336_EHV755C14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2796.2009.02146.x","article-title":"Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study","volume":"267","year":"2010","journal-title":"J Intern Med"},{"key":"key\n\t\t\t\t20170215191336_EHV755C15","first-page":"CD005151","article-title":"Nitrates for acute heart failure syndromes","volume":"8","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170215191336_EHV755C16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ahj.2006.09.005","article-title":"Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure","volume":"153","year":"2007","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ajem.2014.09.009","article-title":"Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic review","volume":"33","year":"2015","journal-title":"Am J Emerg Med"},{"key":"key\n\t\t\t\t20170215191336_EHV755C18","first-page":"1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","author":"VMAC Investigators","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170215191336_EHV755C19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170215191336_EHV755C20","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C21","first-page":"e147","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C22","first-page":"1","volume-title":"Acute heart failure: diagnosing and managing acute heart failure in adults. NICE clinical guideline 187 methods, evidence and recommendations","author":"National Clinical Guideline Centre","year":"2014"},{"key":"key\n\t\t\t\t20170215191336_EHV755C23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1152\/physrev.00001.2012","article-title":"Relaxin family peptides and their receptors","volume":"93","year":"2013","journal-title":"Physiol Rev"},{"key":"key\n\t\t\t\t20170215191336_EHV755C24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2009.198","article-title":"Cardiovascular effects of relaxin: from basic science to clinical therapy","volume":"7","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11897-010-0010-z","article-title":"Relaxin: review of biology and potential role in treating heart failure","volume":"7","year":"2010","journal-title":"Curr Heart Fail Rep"},{"key":"key\n\t\t\t\t20170215191336_EHV755C26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1749-6632.2008.03819.x","article-title":"First clinical experience with intravenous recombinant human relaxin in compensated heart failure","volume":"1160","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"key\n\t\t\t\t20170215191336_EHV755C27","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170215191336_EHV755C28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170215191336_EHV755C29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":"Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes","volume":"61","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C30","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/eurheartj\/eht371","article-title":"Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C31","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/eurheartj\/eht497","article-title":"Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial","volume":"35","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","article-title":"A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure","volume":"35","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C33","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/CIRCHEARTFAILURE.114.001536","article-title":"Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study","volume":"7","year":"2014","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00228-011-1117-1","article-title":"Natriuretic peptides in therapy for decompensated heart failure","volume":"68","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","year":"2006","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t20170215191336_EHV755C36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/eurheartj\/ehu484","article-title":"Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0008-6363(01)00331-5","article-title":"The renal urodilatin system: clinical implications","volume":"51","year":"2001","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t20170215191336_EHV755C38","first-page":"1239","article-title":"Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial","volume":"150","year":"2005","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C39","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/eurheartj\/ehl337","article-title":"Haemodynamic and clinical effects of ularitide in decompensated heart failure","volume":"27","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yjmcc.2011.03.013","article-title":"Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation","volume":"51","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C41","doi-asserted-by":"crossref","first-page":"e52422","DOI":"10.1371\/journal.pone.0052422","article-title":"CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart","volume":"7","year":"2012","journal-title":"PLoS ONE"},{"key":"key\n\t\t\t\t20170215191336_EHV755C42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2008.02.077","article-title":"Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP","volume":"52","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C43","doi-asserted-by":"crossref","first-page":"E2029","DOI":"10.1016\/S0735-1097(11)62029-9","article-title":"A Phase II, Dose-Ranging study with CD-NP, a chimeric natriuretic peptide, in acute decompensated heart failure patients with renal compromise","volume":"57","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C44"},{"key":"key\n\t\t\t\t20170215191336_EHV755C45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd3024","article-title":"Teaching old receptors new tricks: biasing seven-transmembrane receptors","volume":"9","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20170215191336_EHV755C46","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1126\/science.2163110","article-title":"Beta-arrestin: a protein that regulates beta-adrenergic receptor function","volume":"248","year":"1990","journal-title":"Science"},{"key":"key\n\t\t\t\t20170215191336_EHV755C47","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1073\/pnas.041604898","article-title":"Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds","volume":"98","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170215191336_EHV755C48","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1172\/JCI25330","article-title":"Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q\/G alpha I coupling causes hypertrophy and bradycardia in transgenic mice","volume":"115","year":"2005","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170215191336_EHV755C49","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1124\/jpet.110.173005","article-title":"Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance","volume":"335","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20170215191336_EHV755C50","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCHEARTFAILURE.111.962571","article-title":"Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure","volume":"4","year":"2011","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C51","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/CIRCHEARTFAILURE.112.969220","article-title":"TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure","volume":"5","year":"2012","journal-title":"Circ Heart Failure"},{"issue":"(10 Suppl. A)","key":"key\n\t\t\t\t20170215191336_EHV755C52","first-page":"1221","article-title":"TRV027, a \u03b2-arrestin biased ligand at the angiotensin 2 type 1 receptor, produces rapid, reversible changes in hemodynamics in patients with stable systolic heart failure","volume":"61","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C53","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jcph.111","article-title":"First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"53","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C54","first-page":"193","article-title":"Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor: rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure)","volume":"3","year":"2015","journal-title":"JACC Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C55","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.tips.2008.08.005","article-title":"Nitroxyl (HNO): the Cinderella of the nitric oxide story","volume":"29","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"key\n\t\t\t\t20170215191336_EHV755C56","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1089\/ars.2010.3859","article-title":"Playing with cardiac \u201credox switches\u201d: the \u201cHNO way\u201d to modulate cardiac function","volume":"14","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"key\n\t\t\t\t20170215191336_EHV755C57","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/CIRCHEARTFAILURE.113.000632","article-title":"Nitroxyl (HNO): a novel approach for the acute treatment of heart failure","volume":"6","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"(10_S)","key":"key\n\t\t\t\t20170215191336_EHV755C58","article-title":"A phase 1 study of the safety and pharmacokinetics of the intravenous nitroxyl prodrug, CXL-1427","volume":"65","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10741-009-9149-7","article-title":"Role of guanylate cyclase modulators in decompensated heart failure","volume":"14","year":"2009","journal-title":"Heart Fail Rev"},{"key":"key\n\t\t\t\t20170215191336_EHV755C60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11897-010-0045-1","article-title":"Soluble guanylate cyclase modulators in heart failure","volume":"8","year":"2011","journal-title":"Curr Heart Fail Rep"},{"key":"key\n\t\t\t\t20170215191336_EHV755C61","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20170215191336_EHV755C62","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/0091270008322906","article-title":"Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers","volume":"48","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C63","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/CIRCULATIONAHA.108.800292","article-title":"Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure","volume":"119","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170215191336_EHV755C64","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","article-title":"Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C65","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.135","article-title":"Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)","volume":"16","author":"SOCRATES Investigators and Coordinators","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C66","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1517\/13543784.16.9.1449","article-title":"New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+channel blocker","volume":"16","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t20170215191336_EHV755C67","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1034\/j.1399-6576.2000.440210.x","article-title":"Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery","volume":"44","year":"2000","journal-title":"Acta Anaesthesiol Scand"},{"key":"key\n\t\t\t\t20170215191336_EHV755C68","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1751-7133.2009.00133.x","article-title":"Clevidipine for severe hypertension in acute heart failure: a VELOCITY trial analysis","volume":"16","year":"2010","journal-title":"Congest Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C69","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jjcc.2010.06.009","article-title":"Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure","volume":"56","year":"2010","journal-title":"J Cardiol"},{"issue":"(2 Suppl.)","key":"key\n\t\t\t\t20170215191336_EHV755C70","first-page":"S26","article-title":"Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure","volume":"145","year":"2003","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C71","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1592\/phco.30.5.515","article-title":"Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension","volume":"30","year":"2010","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20170215191336_EHV755C72","first-page":"955","article-title":"Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects","volume":"60","year":"2000","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170215191336_EHV755C73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1536\/ihj.53.139","article-title":"Cardioprotective effects of sarcolemmal and mitochondrial K-ATP channel openers in an experimental model of autoimmune myocarditis. Role of the reduction in calcium overload during acute heart failure","volume":"53","year":"2012","journal-title":"Int Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C74","doi-asserted-by":"crossref","first-page":"e52667","DOI":"10.1371\/journal.pone.0052667","article-title":"Nicorandil prevents Galphaq-induced progressive heart failure and ventricular arrhythmias in transgenic mice","volume":"7","year":"2012","journal-title":"PLoS ONE"},{"key":"key\n\t\t\t\t20170215191336_EHV755C75","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00380-012-0252-7","article-title":"Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes","volume":"28","year":"2013","journal-title":"Heart Vessels"},{"key":"key\n\t\t\t\t20170215191336_EHV755C76","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1253\/circj.CJ-11-1110","article-title":"Effects of intravenous nicorandil on the mid-term prognosis of patients with acute heart failure syndrome","volume":"76","year":"2012","journal-title":"Circ J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C77","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal function in advanced decompensated heart failure","volume":"53","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170215191336_EHV755C78","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cardfail.2014.03.003","article-title":"Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study","volume":"20","year":"2014","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C79","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/eurjhf\/hfq132","article-title":"Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study","volume":"12","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C80"},{"key":"key\n\t\t\t\t20170215191336_EHV755C81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000249280","article-title":"Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure \u2013 association with signs and symptoms, hospitalization duration, and 60-day outcomes","volume":"115","year":"2010","journal-title":"Cardiology"},{"key":"key\n\t\t\t\t20170215191336_EHV755C82"},{"key":"key\n\t\t\t\t20170215191336_EHV755C83","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ahj.2015.04.007","article-title":"Worsening heart failure during hospitalization for acute heart failure: insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF)","volume":"170","year":"2015","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170215191336_EHV755C84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"for the REVIVE Heart Failure Study Group","year":"2013","journal-title":"JACC Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C85","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/eurjhf\/hfr060","article-title":"Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF","volume":"13","author":"Pre-Relax-AHF Study Group","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C86","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ejhf.294","article-title":"Agents with vasodilator properties in acute heart failure: how to design successful trials","volume":"17","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20170215191336_EHV755C87","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrd3431","article-title":"Novel therapeutic targets for the treatment of heart failure","volume":"10","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20170215191336_EHV755C88","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.tcm.2013.01.002","article-title":"GPCR biased ligands as novel heart failure therapeutics","volume":"23","year":"2013","journal-title":"Trends Cardiovasc Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/5\/317\/10372865\/ehv755.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T19:01:51Z","timestamp":1503601311000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/2990006\/Agents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,4]]},"references-count":88,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,2,4]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehv755","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,4]]}}}